UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

May 12,
2026

________________

 

NOVO NORDISK A/S

 (Exact name
of Registrant as specified in its charter)

 

 

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F

 

Form 20-F ☒     
     Form 40-F ☐

  

 

 

 

 

 

 

 

Trading in Novo Nordisk shares by board
members, executives and associated persons

 

Bagsværd, Denmark, 12 May 2026 — This company announcement
discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated
persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their
associated persons have reported the transactions to Novo Nordisk.

 

1

Details of the person discharging managerial responsibilities/person closely associated
 

a)
Name of the Board member/Executive/Associated
Person
Caroline Munk
Esbjerg
 

2

Reason for
the notification
 

a)
Position/status
Closely associated
person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
 

b)
Initial notification/Amendment
Initial notification
 

3

Details of
the issuer
 

a)
Name
Novo Nordisk
A/S
 

b)
LEI
549300DAQ1CVT6CXN342
 

4

Details of
the transaction(s)
 

a)
Description of the financial instrument,
type of instrument,
Shares

 

 

 
Identification code
Novo Nordisk
B DK0062498333
 

b)
Nature of the transaction
Shares received
as gift  
 

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 

 
DKK 294.30
50
 
 

 
 
 
 
 

d)
Aggregated
information

 

50
shares
DKK 14,715

 

e)
Date of the transaction
2026-05-07
 

f)
Place of the transaction
Outside a
trading venue
 

 

 

 

 

 

1

Details of the person discharging managerial responsibilities/person closely associated
 

a)
Name of the Board member/Executive/Associated
Person
Sofie Munk
Esbjerg
 

2

Reason for
the notification
 

a)
Position/status
Closely associated
person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
 

b)
Initial notification/Amendment
Initial notification
 

3

Details of
the issuer
 

a)
Name
Novo Nordisk
A/S
 

b)
LEI
549300DAQ1CVT6CXN342
 

4

Details of
the transaction(s)
 

a)
Description of the financial instrument,
type of instrument,
Shares

 

 

 
Identification code
Novo Nordisk
B DK0062498333
 

b)
Nature of the transaction
Shares received
as gift 
 

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 

 
DKK 294.25
50
 
 

 
 
 
 
 

d)
Aggregated
information

 

50
shares
DKK 14,712.50

 

e)
Date of the transaction
2026-05-07
 

f)
Place of the transaction
Outside a
trading venue
 

 

 

 

About Novo Nordisk

Novo Nordisk is a leading global healthcare
company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our
heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For
more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube

 

 

Contacts for further information

 

Media:
 

Ambre James-Brown
Liz Skrbkova (US)

+45 3079 9289
+1 609 917 0632

abmo@novonordisk.com
lzsk@novonordisk.com

 
 

Investors:
 

Michael Novod
Jacob Martin Wiborg Rode

+45 3075 6050
+45 3075 5956

nvno@novonordisk.com
jrde@novonordisk.com

 
 

Max Ung
Sina Meyer

+45 3077 6414
+45 3079 6656

mxun@novonordisk.com
azey@novonordisk.com

 
 

Alex Bruce
Christoffer Sho Togo Tullin

+45 3444 2613
+45 3079 1471

axeu@novonordisk.com
cftu@novonordisk.com

 
 

Mads Berner Bruun
Frederik Taylor Pitter

+45 3075 2936
+1 609 613 0568

mbbz@novonordisk.com
fptr@novonordisk.com

 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé 1

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

www.novonordisk.com
CVR no: 24 25 67 90

   Company
announcement No 31/ 2026

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: May 12, 2026

 

NOVO NORDISK A/S

 

Maziar Mike Doustdar

Chief Executive Officer